Treatment burden in survivors of prostate and colorectal cancers: a qualitative interview study
Objectives
Treatment burden is the workload of healthcare and the impact this has on the individual. Treatment burden is associated with poorer patient outcomes in several chronic diseases. Illness burden has been extensively studied in cancer, but little is known about treatment burden, particularly in those who have completed primary treatment for cancer. The aim of this study was to investigate treatment burden in survivors of prostate and colorectal cancers and their caregivers.
Design
Semistructured interview study. Interviews were analysed using Framework and thematic analysis.
Setting
Participants were recruited via general practices in Northeast Scotland.
Participants
Eligible participants were individuals who had been diagnosed with colorectal or prostate cancer without distant metastases within the previous 5 years and their caregivers. Thirty-five patients and six caregivers participated: 22 patients had prostate and 13 had colorectal cancers (six male, seven female).
Results
The term ‘burden’ did not resonate with most survivors, who expressed gratitude that time invested in cancer care could translate into improved survival. Cancer management was time consuming, but workload reduced over time. Cancer was usually considered as a discrete episode. Individual, disease and health system factors protected against or increased treatment burden. Some factors, such as health service configuration, were potentially modifiable. Multimorbidity contributed most to treatment burden and influenced treatment decisions and engagement with follow-up. The presence of a caregiver protected against treatment burden, but caregivers also experienced burden.
Conclusions
Intensive cancer treatment and follow-up regimens do not necessarily lead to perceived burden. A cancer diagnosis serves as a strong motivator to engage in health management, but a careful balance exists between positive perceptions and burden. Treatment burden could lead to poorer cancer outcomes by influencing engagement with and decisions about care. Clinicians should ask about treatment burden and its impact, particularly in those with multimorbidity.
Trial registration number
Top-30
Journals
|
1
2
|
|
|
BMJ Open
2 publications, 18.18%
|
|
|
Urology
1 publication, 9.09%
|
|
|
Cancer journal (Sudbury, Mass.)
1 publication, 9.09%
|
|
|
Supportive Care in Cancer
1 publication, 9.09%
|
|
|
Journal of the National Cancer Institute. Monographs
1 publication, 9.09%
|
|
|
Healthcare
1 publication, 9.09%
|
|
|
Health Expectations
1 publication, 9.09%
|
|
|
NEJM Catalyst
1 publication, 9.09%
|
|
|
European Journal of Cancer
1 publication, 9.09%
|
|
|
Frontiers in Public Health
1 publication, 9.09%
|
|
|
1
2
|
Publishers
|
1
2
|
|
|
BMJ
2 publications, 18.18%
|
|
|
Elsevier
2 publications, 18.18%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 9.09%
|
|
|
Springer Nature
1 publication, 9.09%
|
|
|
Oxford University Press
1 publication, 9.09%
|
|
|
MDPI
1 publication, 9.09%
|
|
|
Wiley
1 publication, 9.09%
|
|
|
Massachusetts Medical Society
1 publication, 9.09%
|
|
|
Frontiers Media S.A.
1 publication, 9.09%
|
|
|
1
2
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.